MX2014011537A - Formulaciones parenterales para la administracion de antibioticos macrolidos. - Google Patents

Formulaciones parenterales para la administracion de antibioticos macrolidos.

Info

Publication number
MX2014011537A
MX2014011537A MX2014011537A MX2014011537A MX2014011537A MX 2014011537 A MX2014011537 A MX 2014011537A MX 2014011537 A MX2014011537 A MX 2014011537A MX 2014011537 A MX2014011537 A MX 2014011537A MX 2014011537 A MX2014011537 A MX 2014011537A
Authority
MX
Mexico
Prior art keywords
macrolide antibiotics
parenteral formulations
low
therapeutic compounds
formulations
Prior art date
Application number
MX2014011537A
Other languages
English (en)
Spanish (es)
Inventor
David E Pereira
Sara Wu
Prabhavathi Fernandes
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of MX2014011537A publication Critical patent/MX2014011537A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
MX2014011537A 2012-03-27 2013-03-27 Formulaciones parenterales para la administracion de antibioticos macrolidos. MX2014011537A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616196P 2012-03-27 2012-03-27
US201361783026P 2013-03-14 2013-03-14
PCT/US2013/034179 WO2013148891A1 (en) 2012-03-27 2013-03-27 Parenteral formulations for administering macrolide antibiotics

Publications (1)

Publication Number Publication Date
MX2014011537A true MX2014011537A (es) 2015-02-10

Family

ID=49261221

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011537A MX2014011537A (es) 2012-03-27 2013-03-27 Formulaciones parenterales para la administracion de antibioticos macrolidos.

Country Status (15)

Country Link
US (2) US10188674B2 (enExample)
EP (1) EP2830632A4 (enExample)
JP (2) JP6208742B2 (enExample)
KR (1) KR20140139083A (enExample)
CN (1) CN104470527B (enExample)
AU (1) AU2013239696C1 (enExample)
CA (1) CA2868262A1 (enExample)
HK (1) HK1205939A1 (enExample)
IL (2) IL234769A (enExample)
IN (1) IN2014DN08939A (enExample)
MX (1) MX2014011537A (enExample)
NZ (1) NZ700182A (enExample)
RU (1) RU2658050C2 (enExample)
SG (1) SG11201405895UA (enExample)
WO (1) WO2013148891A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2772254A3 (en) 2003-03-10 2015-03-11 Optimer Pharmaceuticals, Inc. Novel Antibacterial Agents
JP5698979B2 (ja) 2007-10-25 2015-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド系抗菌剤の調製プロセス
EP2358379B1 (en) 2008-10-24 2015-12-16 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
RU2608390C2 (ru) 2010-05-20 2017-01-18 Семпра Фармасьютикалз, Инк. Способы получения макролидов и кетолидов, и промежуточных соединений для их получения
WO2012034058A1 (en) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
JP6208742B2 (ja) 2012-03-27 2017-10-04 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗生物質を投与するための非経口製剤
US9861616B2 (en) 2013-03-14 2018-01-09 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
US9751908B2 (en) 2013-03-15 2017-09-05 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
BR112015025159A2 (pt) 2013-04-04 2017-07-18 Harvard College macrolídeos e métodos de sua preparação e uso
JP2017531663A (ja) 2014-10-08 2017-10-26 プレジデント アンド フェローズ オブ ハーバード カレッジ １４員ケトライドならびにそれらの調製および使用の方法
WO2016154591A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
AU2018220172A1 (en) * 2017-02-17 2019-10-03 Cempra Pharmaceuticals, Inc. Triazole-containing macrolides and ophthalmic uses therefor
CN109394200B (zh) * 2018-12-16 2021-10-19 冯兴怀 用于液体治疗、容量管理的微循环脉冲血流监测系统和方法

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1354753A (en) 1919-02-11 1920-10-05 E M Lannes Portable building
US2180006A (en) 1936-09-09 1939-11-14 Eastman Kodak Co Process for the separation and refining of amines
GB891817A (en) * 1959-04-07 1962-03-21 Upjohn Co Improvements in or relating to injectable tetracyclic preparations
GB891617A (en) 1959-09-02 1962-03-14 Clifford Brothers Ltd Lever handle for operating a latch or the spring bolt in a lock
US3843787A (en) * 1969-01-15 1974-10-22 Pierrel Spa Water soluble derivative of erythromycin
US3668282A (en) 1970-05-08 1972-06-06 Stauffer Chemical Co Stabilized mixture employing n-(beta-0,0-dialkyldithiophosphoryl) aryl sulfonamides
US3843767A (en) 1972-03-27 1974-10-22 Du Pont Process for treating fluophosphate ores
SE458505B (sv) * 1979-07-10 1989-04-10 Lepetit Spa Anvaendningen av rifamycin sv och salter daerav foer framstaellning av en beredning foer behandling av reumatoid artrit samt vissa av salterna och deras framstaellning
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
JPS59175414A (ja) * 1983-03-23 1984-10-04 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
DE3860503D1 (de) 1987-09-03 1990-10-04 Pliva Pharm & Chem Works 10-dihydro-10-deoxo-11-azaerythronolid-a-verbindungen,verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung in arzneimitteln und in deren herstellung.
BE1001869A3 (fr) 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
TW271400B (enExample) 1992-07-30 1996-03-01 Pfizer
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
JPH07126172A (ja) 1993-11-05 1995-05-16 Genichiro Soma Ｌｐｓを含む抗ｍｒｓａ剤及び動物用抗ｍｒｓａ剤
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
DE69733370T2 (de) * 1996-09-04 2006-02-02 Abbott Laboratories, Abbott Park 6-o-Substituierte Ketoliden mit antibakteriellen Wirkung
BR9714394A (pt) 1996-12-13 2000-05-16 Lilly Co Eli Inibidores da atividade enzimática de psa
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000074A (es) 1997-06-11 1999-01-08 Pfizer Prod Inc Derivados de macrolidos c-4 sustituidos
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
EP0988308A1 (en) 1997-06-11 2000-03-29 Pfizer Products Inc. 9-oxime erythromycin derivatives
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
DE69918074T2 (de) 1998-03-26 2004-11-04 Fujisawa Pharmaceutical Co., Ltd. Makrolid-formulierung mit verzögerter wirkstoffabgabe
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
KR100317907B1 (ko) 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
TR200102129T2 (tr) 1998-12-10 2002-01-21 Pfizer Products Inc. Karbamat ve karbazat ketolid antibiyotikleri.
TR200102128T2 (tr) 1999-01-27 2001-12-21 Pfizer Products Inc. Ketolid antibiyotikler
CA2292359C (en) 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
FR2789392B1 (fr) 1999-02-04 2001-10-05 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
JP2000351794A (ja) 1999-04-08 2000-12-19 Hokuriku Seiyaku Co Ltd エリスロマイシン誘導体
AR023264A1 (es) 1999-04-08 2002-09-04 Hokuriku Pharmaceutical Derivados de eritromicina
KR100710605B1 (ko) 1999-04-16 2007-04-24 코산 바이오사이언시즈, 인코포레이티드 매크롤라이드 항감염제
CA2370743A1 (en) 1999-04-16 2000-10-26 Dennis Hlasta Ketolide antibacterials
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
AU6183700A (en) 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
AU3337900A (en) 1999-08-09 2001-03-05 Eric Au An apparatus for treating wastewater
US6096922A (en) 1999-11-01 2000-08-01 Air Products And Chemicals, Inc. Process for the synthesis of dialkyl, diaryl, and arylalkyl aminosulfur trifluorides
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
US20020009507A1 (en) 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
ATE338053T1 (de) 2000-03-15 2006-09-15 Hanmi Pharm Ind Co Ltd Verfahren zur herstellung von clarythromycin mit nicht pharmazeutischer qualität
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
FR2821747B1 (fr) 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Suspension de telithromycine a gout masque
ES2261735T3 (es) 2001-05-18 2006-11-16 Chiron Corporation Sistema para la administracion de una formulacion de tobramicina.
FR2826274B1 (fr) 2001-06-21 2003-09-26 Aventis Pharma Sa Formulation pharmaceutique au gout masque et son procede de preparation
AU2002316550A1 (en) 2001-07-03 2003-01-21 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
BR0307898A (pt) 2002-02-22 2004-12-07 Pharmacia Corp Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
JP4638225B2 (ja) 2002-05-30 2011-02-23 ザ スクリプス リサーチ インスティテュート 銅を触媒とするアジドとアセチレンのライゲーション
AU2003276836B2 (en) 2002-06-17 2007-05-10 Epigenesis Pharmaceuticals, Llc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
RS20050008A (sr) 2002-07-08 2007-06-04 Pliva-Istraživački Institut D.O.O., Nova jedinjenja,kompozicije i metode za lečenje inflamatornih oboljenja i stanja
US20040013737A1 (en) 2002-07-19 2004-01-22 Philippe Becourt Taste masked oral composition of telithromycin
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
EP2772254A3 (en) * 2003-03-10 2015-03-11 Optimer Pharmaceuticals, Inc. Novel Antibacterial Agents
US7163924B2 (en) 2003-04-25 2007-01-16 Chiron Corporation Ketolide derivatives
CA2523134A1 (en) 2003-04-25 2004-11-11 Chiron Corporation Pyridyl substituted ketolide antibiotics
DE602004003809T2 (de) 2003-05-13 2007-10-11 Glaxo Group Ltd., Greenford Neue 14- und 15-gliedrige ringverbindungen
WO2005007143A2 (en) 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
GB0402578D0 (en) 2004-02-05 2004-03-10 Cambridge Theranostics Ltd Methods of treatment of atherosclerosis
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
PL1742957T3 (pl) 2004-04-28 2008-05-30 Alembic Ltd Sposób otrzymywania telitromycyny
EP1756135B1 (en) 2004-05-06 2009-08-12 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. Ester linked macrolides useful for the treatment of microbial infections
EP1794171A2 (en) 2004-07-28 2007-06-13 Ranbaxy Laboratories, Ltd. Ketolide derivatives as antibacterial agents
GB0424959D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
GB0424958D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
DE602005019786D1 (de) 2004-12-21 2010-04-15 Pfizer Prod Inc Makrolide
US20080113926A1 (en) 2005-01-14 2008-05-15 Zrinka Ivezic 9A-Carbamoyl-Y-Aminopropyl- And 9A-Thiocabamoyl-Y-Aminopropyl-Azalides With Antimalarial Activity
EP1841437B1 (en) 2005-01-14 2009-04-29 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. 9a-carbamoyl and thiocarbamoyl azalides with antimalarial activity
WO2006106440A1 (en) 2005-01-14 2006-10-12 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Macrolide compounds containing biotin and photo-affinity group for macrolide target identification
WO2006102308A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1b antagonists
CA2609549A1 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EP1904041A2 (en) 2005-07-07 2008-04-02 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
JP5328349B2 (ja) 2005-07-19 2013-10-30 アゼヴァン ファーマスーティカルズ，インコーポレイテッド ベータ−ラクタミルフェニルアラニン、システイン、およびセリン・バソプレッシン拮抗剤
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
US20070167382A1 (en) 2005-11-15 2007-07-19 Nina Finkelstein Crystalline and amorphous forms of telithromycin
US20090075916A1 (en) 2005-11-23 2009-03-19 Upadhyay Dilip J Use of Macrolide Derivatives for Treating Acne
US20090005325A1 (en) 2005-11-23 2009-01-01 Biswajit Bas Ketolide Derivatives as Antibacterial Agents
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
FR2897154B1 (fr) 2006-02-08 2008-03-07 Airbus France Sas Dispositif pour construire et securiser une trajectoire de vol a basse altitude destinee a etre suivie par un aeronef.
CN101045063B (zh) 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
CN103193840A (zh) 2006-05-01 2013-07-10 大正制药株式会社 大环内酯衍生物
CA2654450A1 (en) 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7951905B2 (en) 2006-09-18 2011-05-31 University Of Manitoba Synthesis of carbohydrate-templated amino acids and methods of using same
US8609148B2 (en) 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
RU2469034C2 (ru) 2006-12-04 2012-12-10 Астразенека Аб Химические соединения
JP5025249B2 (ja) 2006-12-15 2012-09-12 Ｎｓｋワーナー株式会社 発進クラッチ
JP5698979B2 (ja) 2007-10-25 2015-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド系抗菌剤の調製プロセス
US20110040078A1 (en) 2007-10-25 2011-02-17 Siegfried Wolf Process for the production of telithromycin
US7795316B1 (en) 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
US20090209547A1 (en) 2008-02-15 2009-08-20 In Jong Kim C-8 halogenated macrolides
EP2358379B1 (en) 2008-10-24 2015-12-16 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
WO2010077730A2 (en) 2008-12-09 2010-07-08 Auspex Pharmaceutical, Inc Indanone inhibitors of acetylcholinesterase
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
CA2764197C (en) 2009-06-03 2017-09-12 Algipharma As Alginate oligomers for use in overcoming multidrug resistance in bacteria
CA2767614C (en) 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
CN109091489A (zh) 2010-03-10 2018-12-28 森普拉制药公司 大环内酯类抗生素的肠胃外制剂
AU2011232627B2 (en) 2010-03-22 2016-03-17 Cempra Pharmaceuticals, Inc. Crystalline forms of a macrolide, and uses therefor
RU2608390C2 (ru) 2010-05-20 2017-01-18 Семпра Фармасьютикалз, Инк. Способы получения макролидов и кетолидов, и промежуточных соединений для их получения
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
WO2012012257A2 (en) 2010-07-19 2012-01-26 Virginia Commonwealth University BIVALENT MULTIFUNCTIONAL LIGANDS TARGETING Aβ OLIGOMERS AS TREATMENT FOR ALZHEIMER'S DISEASE
WO2012030513A2 (en) 2010-08-30 2012-03-08 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
WO2012034058A1 (en) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
WO2012042534A2 (en) 2010-09-28 2012-04-05 Glenmark Generics Limited Processes for the preparation of r-sitagliptin and intermediates thereof
EP2681222B1 (en) 2011-03-01 2018-02-28 Wockhardt Limited Process for preparation of ketolide intermediates
JP6072778B2 (ja) 2011-05-23 2017-02-01 シーイーエム—１０２ ファーマシューティカルズ，インコーポレイテッド フシジン酸を含む組成物およびそのためのパッケージ
US8822450B2 (en) 2011-08-27 2014-09-02 Wockhardt Ltd. 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
JP6208742B2 (ja) 2012-03-27 2017-10-04 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗生物質を投与するための非経口製剤
US9861616B2 (en) 2013-03-14 2018-01-09 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
US9751908B2 (en) 2013-03-15 2017-09-05 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
BR112015025159A2 (pt) 2013-04-04 2017-07-18 Harvard College macrolídeos e métodos de sua preparação e uso
RU2016133471A (ru) 2014-02-14 2018-03-19 Семпра Фармасьютикалс, Инк. Композиции и способы для лечения диабета и заболеваний печени
US20170101365A1 (en) 2014-05-27 2017-04-13 Dipharma Francis S.R.L. Azidoalkylamine salts and their use as intermediates
EP3185864A4 (en) 2014-08-05 2018-03-28 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
WO2016144833A1 (en) 2015-03-06 2016-09-15 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides
WO2018045294A1 (en) 2016-09-02 2018-03-08 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides

Also Published As

Publication number Publication date
KR20140139083A (ko) 2014-12-04
CA2868262A1 (en) 2013-10-03
CN104470527A (zh) 2015-03-25
AU2013239696C1 (en) 2018-11-29
EP2830632A1 (en) 2015-02-04
HK1208622A1 (en) 2016-03-11
JP2015512413A (ja) 2015-04-27
US20190328759A1 (en) 2019-10-31
US20150342977A1 (en) 2015-12-03
AU2013239696A1 (en) 2014-10-09
NZ700182A (en) 2017-02-24
IN2014DN08939A (enExample) 2015-05-22
CN104470527B (zh) 2019-05-28
IL254005B (en) 2019-09-26
IL254005A0 (en) 2017-10-31
HK1205939A1 (en) 2015-12-31
RU2014139169A (ru) 2016-05-20
RU2658050C2 (ru) 2018-06-19
JP6208742B2 (ja) 2017-10-04
EP2830632A4 (en) 2015-10-21
IL234769A (en) 2017-08-31
JP2018030848A (ja) 2018-03-01
SG11201405895UA (en) 2014-10-30
JP6378408B2 (ja) 2018-08-22
WO2013148891A1 (en) 2013-10-03
AU2013239696B2 (en) 2017-12-14
US10188674B2 (en) 2019-01-29

Similar Documents

Publication Publication Date Title
NZ700182A (en) Parenteral formulations for administering macrolide antibiotics
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
PH12014500386A1 (en) Combination treatment for hepatitis c
MX2009005603A (es) Compuestos de urea policiclicos antibacterianos.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2010009163A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211.
WO2012054500A3 (en) Compositions for drug administration
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
EA201390626A1 (ru) Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций
EP4360621A3 (en) Formulations of bendamustine
MX2017010280A (es) Complejos de acetato de abiraterona, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
MX2010013310A (es) Derivados de heterociclil urea para el tratamiento de infecciones bacterianas.
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
FI3383385T4 (fi) Melflufeeniannoskuureja syöpään
EP4591874A3 (en) Pharmaceutical development
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2022013450A (es) Formulaciones farmaceuticas.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2015007731A (es) Formulacion farmaceutica que comprende ciclesonida.
MX2015014905A (es) Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos.
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
WO2014184726A3 (en) Compounds and their use in therapy
UA94177C2 (en) antimicrobial composition